Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment
Fibromyalgia is a condition with widespread muscle pain. Prevalence studies showed that 2% to 7% of the population have fibromyalgia, which affects approximately one million Canadians. Fibromyalgia is most common in women, but it also involves men and children. As with most chronic illnesses, the ca...
Saved in:
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2008-01-01
|
Series: | Pain Research and Management |
Online Access: | http://dx.doi.org/10.1155/2008/959036 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832563913914318848 |
---|---|
author | Janice E Sumpton Dwight E Moulin |
author_facet | Janice E Sumpton Dwight E Moulin |
author_sort | Janice E Sumpton |
collection | DOAJ |
description | Fibromyalgia is a condition with widespread muscle pain. Prevalence studies showed that 2% to 7% of the population have fibromyalgia, which affects approximately one million Canadians. Fibromyalgia is most common in women, but it also involves men and children. As with most chronic illnesses, the causes of fibromyalgia are unknown. However, recent research supports underlying abnormalities in the central nervous system, which supports fibromyalgia as a chronic disease state and valid clinical entity. Pain is the primary symptom, often accompanied by overwhelming fatigue, sleep dysfunction and cognitive impairment. In 1990, the American College of Rheumatology developed diagnostic criteria for the diagnosis of fibromyalgia. Lifestyle changes, including pacing of activities and aerobic exercise, are very important in managing fibromyalgia symptoms. Emotional and behavioural therapy can also be helpful. Controlled trials of antidepressants, gabapentinoids, tramadol, zopiclone and sodium oxybate have shown effectiveness in fibromyalgia patients. Pregabalin and duloxetine were recently approved in the United States. Effective management of fibromyalgia is complex and requires a multidisciplinary treatment approach. Response and tolerance of different therapeutic interventions vary from patient to patient. Recent advances in the pathophysiology of fibromyalgia offer hope for new and improved therapies in the management of this disabling condition. |
format | Article |
id | doaj-art-6849b2f8de934fd49d66f82477f163eb |
institution | Kabale University |
issn | 1203-6765 |
language | English |
publishDate | 2008-01-01 |
publisher | Wiley |
record_format | Article |
series | Pain Research and Management |
spelling | doaj-art-6849b2f8de934fd49d66f82477f163eb2025-02-03T01:12:18ZengWileyPain Research and Management1203-67652008-01-0113647748310.1155/2008/959036Fibromyalgia: Presentation and Management with a Focus on Pharmacological TreatmentJanice E Sumpton0Dwight E Moulin1Department of Pharmacy, Victoria Hospital, London Health Sciences Centre, London, Ontario, CanadaDepartments of Clinical Neurological Sciences and Oncology, University of Western Ontario, London, Ontario, CanadaFibromyalgia is a condition with widespread muscle pain. Prevalence studies showed that 2% to 7% of the population have fibromyalgia, which affects approximately one million Canadians. Fibromyalgia is most common in women, but it also involves men and children. As with most chronic illnesses, the causes of fibromyalgia are unknown. However, recent research supports underlying abnormalities in the central nervous system, which supports fibromyalgia as a chronic disease state and valid clinical entity. Pain is the primary symptom, often accompanied by overwhelming fatigue, sleep dysfunction and cognitive impairment. In 1990, the American College of Rheumatology developed diagnostic criteria for the diagnosis of fibromyalgia. Lifestyle changes, including pacing of activities and aerobic exercise, are very important in managing fibromyalgia symptoms. Emotional and behavioural therapy can also be helpful. Controlled trials of antidepressants, gabapentinoids, tramadol, zopiclone and sodium oxybate have shown effectiveness in fibromyalgia patients. Pregabalin and duloxetine were recently approved in the United States. Effective management of fibromyalgia is complex and requires a multidisciplinary treatment approach. Response and tolerance of different therapeutic interventions vary from patient to patient. Recent advances in the pathophysiology of fibromyalgia offer hope for new and improved therapies in the management of this disabling condition.http://dx.doi.org/10.1155/2008/959036 |
spellingShingle | Janice E Sumpton Dwight E Moulin Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment Pain Research and Management |
title | Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment |
title_full | Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment |
title_fullStr | Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment |
title_full_unstemmed | Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment |
title_short | Fibromyalgia: Presentation and Management with a Focus on Pharmacological Treatment |
title_sort | fibromyalgia presentation and management with a focus on pharmacological treatment |
url | http://dx.doi.org/10.1155/2008/959036 |
work_keys_str_mv | AT janiceesumpton fibromyalgiapresentationandmanagementwithafocusonpharmacologicaltreatment AT dwightemoulin fibromyalgiapresentationandmanagementwithafocusonpharmacologicaltreatment |